Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupHKSE:02005 -0.42%86 Days Payable is 51.61 as of Dec. 2025, which is 1% above its 10-year median of 51.09. GuruFocus rates HKSE:02005 with a GF Score™ of 86/100 and a GF Value™ of HK$3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 926 Drug Manufacturers companies, SSY Group ranks worse than 67.39% on this metric.
SSY Group's average Accounts Payable for the
six
months ended in Dec. 2025 was HK$333 Mil. SSY Group's Cost of Goods Sold for the
six
months ended in Dec. 2025 was HK$1,178 Mil.
Hence, SSY Group's Days Payable for the
six
months ended in Dec. 2025 was 51.61.
The historical rank and industry rank for SSY Group's Days Payable or its related term are showing as below:
HKSE:02005'
s Days Payable Range Over the Past 10 Years
Min: 33.24 Med: 51.09 Max: 70.72
Current: 60.65
During the past 13 years, SSY Group's highest Days Payable was 70.72. The lowest was 33.24. And the median was 51.09.
HKSE:02005's Days Payable is ranked worse than 67.39% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs HKSE:02005: 60.65
SSY Group's Days Payable
declined
from Dec. 2024 (66.50) to Dec. 2025 (51.61).
It may suggest that SSY Groupaccelerated paying its suppliers.
SSY Group Days Payable Related Terms
SSY Group Days Payable Historical Data
* Premium members only.
The historical data trend for SSY Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Days Payable distribution charts can be found below:
* The bar in red indicates where SSY Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SSY Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a Days Payable of 51.61 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SSY Group and its competitors. This is near median its historical median of 51.09. Over the past decade, SSY Group's Days Payable has ranged from 33.24 to 70.72. According to the industry distribution chart, SSY Group ranks #624 out of 926 companies in the Drug Manufacturers industry, placing it in the top 67.4%.
Is SSY Group's Days Payable too high?
SSY Group's current Days Payable of 51.61 is near median its 10-year median of 51.09. Over the past 10 years, this metric has ranged from a low of 33.24 to a high of 70.72. The Drug Manufacturers industry median Days Payable is 90.22. SSY Group's value of 51.61 is 42.8% below this industry median. Based on the distribution chart, SSY Group ranks #624 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #624 out of 926 companies for Days Payable. This places SSY Group in the lower half of its industry. The industry median Days Payable is 90.22. SSY Group's value of 51.61 is 42.8% below this benchmark. Historically, SSY Group's own Days Payable has ranged from 33.24 to 70.72 over the past decade. While the company's 10-year median is 51.09 vs. the industry median of 90.22, SSY Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Days Payable of 51.61 is 42.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Days Payable is 51.61, which is near median its own 10-year median of 51.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.04, compared to a current price of HK$2.39 — trading 21.4% below its estimated fair value. The current Days Payable is 51.61, which is near median its 10-year median of 51.09 and 42.8% below the Drug Manufacturers industry median of 90.22. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current Days Payable is 51.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.39 is trading 21.4% below its estimated GF Value™ of HK$3.04.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
Days Payable: 51.61 (near median its 10-year median of 51.09)
GF Value™: HK$3.04 vs. price of HK$2.39 (21.4% below fair value)
Industry Position: 42.8% below the Drug Manufacturers median (#624 of 926)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for HKSE:02005
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
